68Ga-DOTA-Tyr3-octreotide PET in neuroendocrine tumors: comparison with somatostatin receptor scintigraphy and CT

What Was Tested

Researchers studied Octreotide and Somatostatin in this clinical trial, phase ii publication.

The aim of this study was to evaluate the diagnostic value of a new somatostatin analog, (68)Ga-labeled 1,4,7,10-tetraazacyclododecane-N,N',N'',N'''-tetraacetic acid-d-Phe(1)-Tyr(3)-octreotide ((68)Ga-DOTA-TOC), for PET in patients with known or suspected neuroendocrine tumors.

Why It Was Studied

PET was compared with conventional scintigraphy and dedicated CT.

Who Took Part

According to the abstract, 48 men were involved.

PubMed indexes the participants as adults, middle-aged adults and older adults, both men and women.

For analysis, patients were divided into 3 groups: detection of unknown primary tumor in the presence of clinical or biochemical suspicion of neuroendocrine malignancy (n = 13 patients), initial tumor staging (n = 36 patients), and follow-up after therapy (n = 35 patients).

Each patient received 100-150 MBq (68)Ga-DOTA-TOC.

How the Study Was Run

Imaging results of PET were compared with (99m)Tc-labeled hydrazinonicotinyl-Tyr(3)-octreotide ((99m)Tc-HYNIC-TOC) and (111)In-DOTA-TOC.

CT was also performed on every patient using a multidetector scanner.

Each imaging modality was interpreted separately by observers who were unaware of imaging findings before comparison with PET.

The gold standard for defining true-positive (TP), true-negative (TN), false-positive (FP), and false-negative (FN) results was based on all available histologic, imaging, and follow-up findings.

What Was Measured

The subject headings attached to it are Gallium Radioisotopes, Octreotide, Positron-Emission Tomography, Radionuclide Imaging, Receptors, Somatostatin, Tomography, X-Ray Computed and Tyrosine.

What This Means in Plain Language

This is a clinical trial, phase ii of Octreotide and Somatostatin in 48 men.

Its findings take up roughly 6 sentences of the abstract and are left out here on purpose; the source paper is the place to read them.

The publication is from 2007 (Journal of nuclear medicine : official publication, Society of Nuclear Medicine), a journal based in United States.

More context: the Octreotide compound page and the Somatostatin compound page, all human trials.